Genotypic and phenotypic resistance of pandemic A/H1N1 influenza viruses circulating in Germany

Antiviral Research

Volumn 89, Issue 1, 2011, Pages 115-118

  Duwe, Susanne C ^a   Wedde, Marianne ^a   Birkner, Patricia ^a   Schweiger, Brunhilde ^a  

^a ROBERT KOCH INSTITUTE   (Germany)

Author keywords

Antiviral drug; H274Y; Oseltamivir resistance; Pandemic A H1N1 virus; Pyrosequencing

Indexed keywords

MOLECULAR MARKER; OSELTAMIVIR; PROTEIN M2; ZANAMIVIR;

ADULT; ARTICLE; CHILD; DRUG SENSITIVITY; FEMALE; FLUORESCENCE ANALYSIS; GENOTYPE; GERMANY; HIGH THROUGHPUT SCREENING; HUMAN; INFLUENZA VIRUS A H1N1; MALE; NONHUMAN; PANDEMIC INFLUENZA; PHENOTYPE; PRESCHOOL CHILD; PRIORITY JOURNAL; PYROSEQUENCING; SCHOOL CHILD; VIRUS MUTATION; VIRUS RESISTANCE;

ADULT; AMINO ACID SUBSTITUTION; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, VIRAL; FEMALE; GERMANY; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MUTATION, MISSENSE; NEURAMINIDASE; OSELTAMIVIR; VIRAL MATRIX PROTEINS; VIRAL PROTEINS; YOUNG ADULT; ZANAMIVIR;

ORTHOMYXOVIRIDAE;

EID: 78650885838     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2010.11.001     Document Type: Article

References (32)

1. Abed Y., Baz M., Boivin G. Impact of neuraminidase mutations conferring influenza resistance to neuraminidase inhibitors in the N1 and N2 genetic backgrounds. Antivir. Ther. 2006, 11(8):971-976.
2. Bean W.J., Threlkeld S.C., Webster R.G. Biologic potential of amantadine-resistant influenza A virus in an avian model. J. Infect. Dis. 1989, 159:1050-1056.
3. Bright R.A., Medina M.J., Xu X., Perez-Oronoz G., Wallis T.R., Davis X.M., Povinelli L., Cox N.J., Klimov A.I. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 2005, 366:1175-1181.
4. Davies W.L., Grunert R.R., Haff R.F., McGahen J.W., Neumayer E.M., Paulshock M., Watts J.C., Wood T.R., Hermann E.C., Hoffmann C.E. Antiviral activity of 1-adamantanamine (amantadine). Science 1964, 144:862-863.
5. Deyde V.M., Xu X., Bright R.A., Shaw M., Smith C.B., Zhang Y., Shu Y., Gubareva L.V., Cox N.J., Klimov A.I. Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. J. Infect. Dis. 2007, 196:249-257.
6. Deyde V.M., Okomo-Adhiambo M., Sheu T.G., Wallis T.R., Fry A., Dharan N., Klimov A.I., Gubareva L.V. Pyrosequencing as a tool to detect molecular markers of resistance to neuraminidase inhibitors in seasonal influenza A viruses. Antivir. Res. 2009, 81:16-24.
7. Deyde V.M., Sheu T.G., Trujillo A.A., Okomo-Adhiambo M., Garten R., Klimov A.I., Gubareva L.V. Detection of molecular markers of drug resistance in 2009 pandemic influenza A (H1N1) viruses by pyrosequencing. Antimicrob. Agents Chemother. 2010, 54:1102-1110.
8. Duwe S., Schweiger B. A new and rapid genotypic assay for the detection of neuraminidase inhibitor resistant influenza A viruses of subtype H1N1, H3N2, and H5N1. J. Virol. Methods 2008, 153:134-141.
9. Govorkova E.A., Leneva I.A., Goloubeva O.G., Bush K., Webster R.G. Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses. Antimicrob. Agents Chemother. 2001, 45:2723-2732.
10. Harvala H., Gunson R., Simmonds P., Hardie A., Bennett S., Scott F., Roddie H., McKnight J., Walsh T., Rowney D., Clark A., Bremner J., Aitken C., Templeton K. The emergence of oseltamivir-resistant pandemic influenza A(H1N1) 2009 virus amongst hospitalised immunocompromised patients in Scotland, November-December 2009. Euro Surveill. 2010, 15:19536.
11. Hay A.J., Zambon M.C., Wolstenholme A.J., Skehel J.J., Smith M.H. Molecular basis of resistance of influenza A viruses to amantadine. J. Antimicrob. Chemother. 1986, 18:19-29.
12. Hayden F.G., Hay A.J. Emergence and transmission of influenza A viruses resistant to amantadine and rimantadine. Curr. Top. Microbiol. Immunol. 1992, 176:119-130.
13. Hurt A.C., Holien J.K., Parker M., Kelso A., Barr I.G. Zanamivir-resistant influenza viruses with a novel neuraminidase mutation. J. Virol. 2009, 83:10366-10373.
14. Janies D.A., Voronkin I.O., Studer J., Hardman J., Alexandrov B.B., Treseder T.W., Valson C. Selection for resistance to oseltamivir in seasonal and pandemic H1N1 influenza and widespread co-circulation of the lineages. Int. J. Health Geogr. 2010, 9:13.
15. Lackenby A., Hungnes O., Dudman S.G., Meijer A., Paget W.J., Hay A.J., Zambon M.C. Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe. Euro Surveill. 2008, 13:8026.
16. Lackenby A., Democratis J., Siqueira M.M., Zambon M.C. Rapid quantitation of neuraminidase inhibitor drug resistance in influenza virus quasispecies. Antivir. Ther. 2008, 13:809-820.
17. McKimm-Breschkin J.L. Resistance of influenza viruses to neuraminidase inhibitors - a review. Antivir. Res. 2000, 47:1-17.
18. McKimm-Breschkin J.L. Neuraminidase inhibitors for the treatment and prevention of influenza. Expert Opin. Pharmacother. 2002, 3:103-112.
19. Meijer A., Lackenby A., Hungnes O., Lina B., van-der-Werf S., Schweiger B., Opp M., Paget J., van-de-Kassteele J., Hay A., Zambon M. Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007-08 season. Emerg. Infect. Dis. 2009, 15:552-560.
20. Moscona A. Neuraminidase inhibitors for influenza. N. Engl. J. Med. 2005, 353:1363-1373.
21. Potier M., Beauregard G., Belisle M., Mameli L., Hong V.N., Melancon S.B., Dallaire L. Neuraminidase activity in the mucolipidoses (types I, II and III) and the cherry-red spot myoclonus syndrome. Clin. Chim. Acta 1979, 99(2):97-105.
22. Schulze M., Nitsche A., Schweiger B., Biere B. Diagnostic approach for the differentiation of the pandemic influenza A(H1N1)v virus from recent human influenza viruses by real-time PCR. PLoS One 2010, 5(4).
23. Sheu T.G., Deyde V.M., Okomo-Adhiambo M., Garten R.J., Xu X., Bright R.A., Butler E.N., Wallis T.R., Klimov A.I., Gubareva L.V. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob. Agents Chemother. 2008, 52:3284-3292.
24. Szecsenyi J., Uphoff H., Ley S., Brede H.D. Influenza surveillance: experiences from establishing a sentinel surveillance system in Germany. J. Epidemiol. Commun. Health 1995, 49(Suppl 1):9-13.
25. Tsunoda A., Maassab H.F., Cochran K.W., Eveland W.C. Antiviral activity of alpha-methyl-1-adamantanemethylamine hydrochloride Antimicrob. Agents Chemother. (Bethesda) 1965, 5:553-560.
26. Wang B., Dwyer D.E., Blyth C.C., Soedjono M., Shi H., Kesson A., Ratnamohan M., McPhie K., Cunningham A.L., Saksena N.K. Detection of the rapid emergence of the H275Y mutation associated with oseltamivir resistance in severe pandemic influenza virus A/H1N1 09 infections. Antivir. Res. 2010, 87:16-21.
27. WHO, 2008. (accessed 13.06.08). http://www.who.int/csr/disease/influenza/ResistanceTable200806013.pdf.
28. WHO, 2009a. New influenza A (H1N1) virus: WHO guidance on public health measures, 11 June 2009. Wkly Epidemiol. Rec. 84, 261-264 (accessed 11.06.09).
29. WHO, 2009b. Influenza A(H1N1) M2 detailed pyrosequencing protocol for antiviral susceptibility testing. Available at: (accessed 13.05.09). http://www.who.int/csr/resources/publications/swineflu/M2_DetailedPyrosequencing_20090513.pdf.
30. WHO, 2009c. Briefing note. Available at: (accessed 20.08.09). http://www.who.int/csr/disease/swineflu/notes/h1n1_use_antivirals_20090820/en/index.html.
31. WHO, 2009d. Weekly epidemiological record. Available at: (accessed 30.10.09). http://www.who.int/wer/2009/wer8444.pdf.
32. WHO, 2010. Weekly report. Available at (accessed 09.07.2010). http://www.who.int/csr/disease/swineflu/oseltamivirresistant20100709.pdf.